Beam Therapeutics BEAM 深 沪
等待开盘 10-01 09:30:00 美东时间
24.75
+0.230
+0.94%
华盛通- 最 高25.1899
- 今 开24.80
- 成交量 80.21万股
- 最 低 24.46
- 昨 收 24.52
- 总市值 25.56亿
- 52周最高 38.26
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 20.23
- 委 比 -98.50%
- 总股本 1.03亿
- 历史最高 138.522
- 量 比 0.60
- 振 幅 2.98%
- 历史最低 13.00
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short. ONDS stock is heavily shorted. See all of the details here. A Benzinga Pro screen of stocks with market caps above $2 billion a...
09-26 02:00
Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”
周三，美股基因编辑公司股价走低。此前，Anthropic宣布，其AI模型Claude“自主发现”了一种类似于基因编辑工具CRISPR的新型酶系统。 个股方面，...
09-24 07:21
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Muse一夜爆红！“木头姐”大手笔增持Meta，加码医疗与生物科技
当地时间9月22日，“木头姐”Cathie Wood旗下方舟投资（ARK Invest）公布的每日交易纪录显示，持股重心明显偏向大型AI平台与基因精准医疗，同时...
09-23 09:49
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the same companies. ARKG bought about $4.5 million of Ionis Pharmaceuticals Inc (NASDAQ:IONS), nearly $3 million of Veracyte Inc (NASDAQ:VCYT),...
09-22 22:40
美股知名投资人最新调仓曝光：“木头姐”大举买入Meta，同时减持CrowdStrike
“木头姐”凯茜·伍德旗下ARK Invest公布9月21日交易记录，当天最受关注的操作是大举买入Meta，同时减持CrowdStrike，并继续调整医疗科技...
09-22 14:42
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD
With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating ...
09-08 18:05
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302, a liver-targeted base editing therapy, shows promise as a one-time treatment for alpha-1 antitrypsin deficiency (AATD), addressing both lung and liver manifestations. Clinical data from a Phase 1/2 trial demonstrate sustained increases in functional AAT levels, reduction in mutant Z-AAT and toxic Z-polymers, and improved AAT function under physiological control. The treatment was generally well-tolerated, with mild-to-moderate infusion-...
09-08 10:00
Most shorted stocks on Wall Street
As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% ...
09-02 22:28
